These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18220753)

  • 1. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure.
    Beghi E; Mennini T; Bendotti C; Bigini P; Logroscino G; Chiò A; Hardiman O; Mitchell D; Swingler R; Traynor BJ; Al-Chalabi A
    Curr Med Chem; 2007; 14(30):3185-200. PubMed ID: 18220753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model.
    Wang R; Zhang D
    Eur J Neurosci; 2005 Nov; 22(9):2376-80. PubMed ID: 16262676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy.
    Strong MJ
    Expert Opin Investig Drugs; 2004 Dec; 13(12):1593-614. PubMed ID: 15566317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.
    Hodgkinson VL; Lounsberry J; Mirian A; Genge A; Benstead T; Briemberg H; Grant I; Hader W; Johnston WS; Kalra S; Linassi G; Massie R; Melanson M; O'Connell C; Schellenberg K; Shoesmith C; Taylor S; Worley S; Zinman L; Korngut L
    Can J Neurol Sci; 2018 Nov; 45(6):652-659. PubMed ID: 30430962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.
    Moujalled D; White AR
    CNS Drugs; 2016 Mar; 30(3):227-43. PubMed ID: 26895253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders.
    Goutman SA
    Continuum (Minneap Minn); 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1332-1359. PubMed ID: 28968365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research in amyotrophic lateral sclerosis: what is new in 2009?].
    Pradat PF; Attarian S; Camdessanché JP; Carluer L; Cintas P; Corcia P; Echaniz-Laguna A; Gonzalez-Bermejo J; Guy N; Nicolas G; Perez T; Soriani MH; Vandenberghe N; Verschueren A;
    Rev Neurol (Paris); 2010; 166(8-9):683-98. PubMed ID: 20472259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (Review).
    Martin LJ; Price AC; Kaiser A; Shaikh AY; Liu Z
    Int J Mol Med; 2000 Jan; 5(1):3-13. PubMed ID: 10601567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2000; (2):CD001447. PubMed ID: 10796796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is magnetic resonance imaging a plausible biomarker for upper motor neuron degeneration in amyotrophic lateral sclerosis/primary lateral sclerosis or merely a useful paraclinical tool to exclude mimic syndromes? A critical review of imaging applicability in clinical routine.
    Rocha AJ; Maia Júnior AC
    Arq Neuropsiquiatr; 2012 Jul; 70(7):532-9. PubMed ID: 22836461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Update on fundamental and clinical research in amyotrophic lateral sclerosis].
    Pradat PF; Camdessanché JP; Carluer L; Cintas P; Corcia P; Danel-Brunaud V; Echaniz-Laguna A; Gonzalez J; Nicolas G; Vandenberghe N; Verschueren A;
    Rev Neurol (Paris); 2009; 165(6-7):532-41. PubMed ID: 19419744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organophosphate neurotoxicity to the voluntary motor system on the trail of environment-caused amyotrophic lateral sclerosis: the known, the misknown, and the unknown.
    Merwin SJ; Obis T; Nunez Y; Re DB
    Arch Toxicol; 2017 Aug; 91(8):2939-2952. PubMed ID: 28070599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical characteristics of amyotrophic lateral sclerosis subsets].
    Pradat PF; Bruneteau G
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S29-4S33. PubMed ID: 17128087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis.
    Mitropoulos K; Katsila T; Patrinos GP; Pampalakis G
    OMICS; 2018 Jan; 22(1):52-64. PubMed ID: 29356625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excitotoxicity and amyotrophic lateral sclerosis.
    Van Damme P; Dewil M; Robberecht W; Van Den Bosch L
    Neurodegener Dis; 2005; 2(3-4):147-59. PubMed ID: 16909020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
    Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
    J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in ALS: what did we learn from recent trials in humans?
    Meininger V
    Neurodegener Dis; 2005; 2(3-4):208-14. PubMed ID: 16909027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidemiology of amyotrophic lateral sclerosis.
    Talbott EO; Malek AM; Lacomis D
    Handb Clin Neurol; 2016; 138():225-38. PubMed ID: 27637961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.